anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Larimar Therapeutics · pitchdeck

Larimar Therapeutics | Investor Presentation Deck | 32 slides

32 pages · 5 arc beats · 3 loops

Pitchdeck Download JSON
Unlock

Larimar Therapeutics | Investor Presentation Deck | 32 slides

Larimar Therapeutics · 2022-10
arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON
Narrative range 10 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 7 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides Solution 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides Traction 6 slides 100% 6/6 slides 100% 6/6 slides · 32 hits
— 0/6 slides
— 0/6 slides
16.7% 1/6 slides 100% 6/6 slides 100% 6/6 slides Roadmap 1 slides 100% 1/1 slides 100% 1/1 slides · 5 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides
— 0/1 slides
Executive Summary 1 slides 100% 1/1 slides 100% 1/1 slides · 6 hits
— 0/1 slides
100% 1/1 slides
— 0/1 slides
100% 1/1 slides
— 0/1 slides

Slide inventory

32
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detail
02
other
Open slide detail
03
summarize
Open slide detailBeat · Executive Summary
04
The slide uses a timeline framework to demonstrate the longevity of IP protection.present_framework
Open slide detail
05
The slide uses a medical context to establish the urgency and market need for a new therapy.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
06
The slide uses a comparison frame to illustrate the mechanism of action for the drug candidate.present_solution
Open slide detailBeat · SolutionLoop · Quick Win Big Bet
07
The slide outlines a 28-day treatment period with daily administration, targeting Friedreich's ataxia patients.plan_implementation
Open slide detailBeat · Roadmap
08
FA likely refers to Friedreich's Ataxia; FXN refers to frataxin protein.show_traction
Open slide detailBeat · TractionLoop · Hypothesis Test
09
The slide uses a process flow diagram to show the relationship between SAD and MAD trials.present_framework
Open slide detailBeat · TractionLoop · Hypothesis Test
10
The slide details the dosing schedule (13 days) and specific sampling days for buccal cells, skin, and platelets across three cohorts with different dosages.analyze_data
Open slide detailBeat · TractionLoop · Hypothesis Test
11
The slide displays two dot plots with error bars representing median and 25th/75th percentiles for different dose cohorts over time.show_traction
Open slide detailBeat · TractionLoop · Hypothesis Test
12
The chart displays a longitudinal study of FXN concentration across different dose groups (Placebo, 25mg, 50mg, 100mg) at Baseline, Day 4/7, and Day 13.show_traction
Open slide detailBeat · TractionLoop · Hypothesis Test
13
The slide uses a two-part structure to address clinical safety and non-clinical toxicology findings.show_traction
Open slide detailBeat · TractionLoop · Hypothesis Test
14
The slide uses a horizontal layout with four distinct trial descriptions, each paired with an icon.plan_implementation
Open slide detail
15
The slide uses a simple three-row layout to summarize the drug's purpose, current data status, and future milestones.summarize
Open slide detail
16
summarize
Open slide detail
17
state_next_steps
Open slide detail
18
appendix
Open slide detail
19
Standard clinical trial demographic table.analyze_data
Open slide detail
20
Clinical trial data table showing age at onset, age at diagnosis, and assistive device usage.analyze_data
Open slide detail
21
The slide displays two dot plots with error bars representing median and 25th/75th percentiles.show_traction
Open slide detail
22
The slide presents two dot plots with error bars representing median and 25th/75th percentiles for FXN concentration and change from baseline.show_traction
Open slide detail
23
analyze_data
Open slide detail
24
The slide uses a standard corporate team bio layout with 10 members arranged in two rows of five.other
Open slide detail
25
The slide serves as a credibility-building asset by showcasing alignment with a key patient advocacy group.establish_context
Open slide detail
26
The slide presents the Scientific Advisory Board members with headshots and brief professional biographies.other
Open slide detail
27
The slide uses a two-column list format to contrast cardiac and neurologic study outcomes.show_traction
Open slide detail
28
Kaplan-Meier survival curve showing significant separation between treatment and vehicle groups.show_traction
Open slide detail
29
The slide uses a bulleted list with checkmarks to summarize key findings from a specific mouse model study.show_traction
Open slide detail
30
Data shows functional replacement of hFXN and normalization of gene expression.show_traction
Open slide detail
31
Data presented as line charts with error bars, comparing KO: CTI-1601, KO: Vehicle, and Wild-type: Vehicle.show_traction
Open slide detail
32
Data presented as line charts showing percent change over time (weeks 4 and 8) for Ejection Function and Fractional Shortening.show_traction
Open slide detail